ArticleClinical and experimental nephrology2026
Urinary thrombin as a non-invasive biomarker in renal diseases: a possible role in the detection of segmental sclerosis lesions in IgA nephropathy.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThrombin is a serine protease that plays an important role in blood coagulation and has been implicated in kidney diseases, particularly glomerular disorders. In this study, we aimed to evaluate urinary thrombin in different types of kidney disease and investigate whether it can be used as a biomarker for the presence of segmental sclerosis lesions in IgA nephropathy.
methodsWe enrolled 151 patients aged ≥ 18 years who underwent renal biopsy at Kumamoto University Hospital or two of its affiliate hospitals between November 2016 and September 2021. Urine samples were obtained from patients, and urinary thrombin antigen levels were measured using a previously established highly sensitive enzyme-linked immunosorbent assay. We evaluated urinary thrombin in different types of kidney disease, focusing on IgA nephropathy, and assessed the association between urinary thrombin and histological severity classification (Oxford classification), especially S lesions.
resultsAmong the patients with kidney disease, thrombinuria was more prevalent in those with focal segmental glomerulosclerosis [60%; 9/15]. In 34 patients with IgA nephropathy, the logistic regression model, using the presence of S lesions as the outcome variable, demonstrated that the odds ratios for thrombinuria and proteinuria were 7.20 and 2.82, respectively. The areas under the receiver operating characteristic curve (AUROC) regarding the models for thrombinuria and proteinuria were 0.73 and 0.56, respectively, with both differences being significant (p = 0.04).
conclusionsOur findings suggest that thrombinuria may be a novel biomarker for kidney disease, particularly for segmental sclerosis lesions in IgA nephropathy.
Indexed as
Identifiers
41627647What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.